MarketPulse

Diffusphere technology

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Eupraxia Pharmaceuticals Advances EP-104GI Data Ahead of Key Medical Conference

Eupraxia Pharmaceuticals to present Phase 1b/2 clinical data for EP-104GI at Digestive Disease Week 2026, showcasing efficacy in eosinophilic esophagitis treatment.
EPRXEP-104GIeosinophilic esophagitis
GlobeNewswire Inc.GlobeNewswire Inc.··Eupraxia Pharmaceuticals Inc.

Eupraxia's EE Drug Hits Key Milestone With 90% Tissue Improvement in Phase Data

Eupraxia Pharmaceuticals reports positive Phase 1b/2a data for EP-104GI in eosinophilic esophagitis, showing 90% tissue improvement and strong safety profile.
EPRXbiotechdrug delivery
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Eupraxia Raises $63.2M, Eyes 2028 as Cash-Runway Extends Despite Rising Losses

Eupraxia Pharmaceuticals closed $63.2M offering, boosting cash to $80.5M with runway through H2 2028. Q4 losses doubled to $16.7M amid clinical progress in eosinophilic esophagitis treatment.
EPRXpublic offeringdrug delivery
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Eupraxia Pharmaceuticals Raises $55M Through Public Offering to Fund GI Pipeline

Eupraxia Pharmaceuticals raises $55M via public offering to advance EP-104GI for eosinophilic esophagitis through Phase 2/3 development and expand GI pipeline.
EPRXclinical trialspublic offering